Pediatric Precision MedicineGettinG it RiGht the FiRst time FoR Kids

August 30, 2016

PrograM Faculty J. Steven Leeder, PharmD, PhDmarion merrell dow / missouri endowed Chair in Pediatric Clinical PharmacologyProfessor of Pediatrics, University of missouri – Kansas CityProfessor of Pediatrics and Pharmacology, University of KansasAssociate Chairman, department of Pediatrics, Children’s mercy Clinical Pharmacology, toxicology and therapeutic innovation, Children’s mercy

Sara Van Driest, MD, PhD, FAAPAssistant Professor of Pediatrics, Vanderbilt Universitydivision of General Pediatrics, Vanderbilt Children’s hospital

G. Bradley Schaefer, MD, FAAPArkansas Children’s hospital Committee for the Future endowed Chair in GeneticsProfessor of Genetics and Pediatrics, University of Arkansas for medical sciencesChief, section on Genetics and metabolismCo-director, Precision medicine initiative, Arkansas Children’s hospital

Gregory L. Kearns, PharmD, PhD, FAAPSenior Vice President and Chief Research Officer, Arkansas Children’s, Inc.President, Arkansas Children’s Research instituteProfessor of Pediatrics, University of Arkansas for medical sciences

Laura P. James, MD, FAAPAssociate Vice Chancellor for Clinical and translational Research and director, translational Research institute, University of Arkansas for medical sciencesProfessor of Pediatrics, University of Arkansas for medical sciencesChief, section on Pediatric Pharmacology and medical toxicology, Arkansas Children’s hospital

Kathleen A. Neville, MD, MS, MBA, FAAPProfessor of Pediatrics, University of Arkansas for medical sciencesmember, sections of Pediatric Clinical Pharmacology and medical toxicology, and Section on Hematology/Oncology, Arkansas Children’s, Inc.director, experimental therapeutics Unit, Arkansas Children’s hospital

Richard Frye, MD, PhD, FAAPAssociate Professor of Pediatrics, University of Arkansas for medical sciencesdirector of Autism Research, Arkansas Children’s Research institutedirector of the Autism multispecialty Precision medicine Clinic, Arkansas Children’s hospitalCo-director, neurometabolic Clinic, Arkansas Children’s hospital

PrograM sPonsorsArkansas Children’s hospitalArkansas Children’s Research institutedepartment of Pediatrics, University of Arkansas for medical sciences

agenda8:00 AM Introductions & Welcome: Dr. Gregory Kearns Ms. Marcy Doderer, FACHE President and CEO, Arkansas Children’s, Inc. Pope moseley, md Professor and dean, school of medicine, UAms

Richard F. Jacobs, MD, FAAP, FIDSA Robert H. Fiser, Jr., Professor of Pediatrics Professor and Chairman, department of Pediatrics Pediatrician-in-Chief, Arkansas Children’s hospital

8:15 AM Pediatric Grand Rounds:

Overcoming Cognitive Inertia: Changing the Way We Think to Address the Challenges of Precision Therapeutics in Children J. Steven Leeder, PharmD, PhD Children’s mercy hospital, Kansas City, mo

9:00 AM Break

9:10 AM GOLDILOCKS – a Paradigm for Precision Medicine for Kids J Steven Leeder, PharmD, PhD

9:50 AM Big Data for Small Patients: Leveraging the EMR to Improve our Care of Children sara van driest, md, Phd, FAAP Vanderbilt University, nashville, tn

1030 AM Break

10:45 AM Pharmacokinetics and Pharmacodynamics – The Two Other Necessary Tools to Deliver Precision Therapeutics Gregory L. Kearns, PharmD, PhD, FAAP

11:15 AM Precision Medicine at Arkansas Children’s Hospital: What, Where, When and How J. Bradley Schaefer, MD

12:00 PM Break and Lunch Distribution

12:15 PM Panel Discussion

Moderator: Laura James, MD

Panel: J. Steven Leeder, PharmD, PhD sara van driest, md, Phd J. Bradley Schaefer, MD Kathleen neville, md Richard Frye, md, Phd

1:00 PM Speaker’s Luncheon

J. Steven Leeder, PharmD, PhD Dr. Leeder is the Marion Merrell Dow/Missouri Endowed Chair in Pediatric Clinical Pharma-cology and director, division of Clinical Pharmacology, toxicology and therapeutic innova-tion at Children’s Mercy Hospitals and Clinics (CMH), Kansas City, Missouri. He serves as Associate Chair-Research, department of Pediatrics and holds faculty appointments as Professor of Pediatrics and Pharmacology at the University of missouri-Kansas City; Cour-tesy Professor of Pharmaceutical Chemistry in the school of Pharmacy at the University of Kansas (Lawrence, KS); and Adjunct Professor of Pharmacology, Toxicology and Therapeu-tics at the University of Kansas Medical Center (Kansas City, KS).

Dr. Leeder is an elected member of the American Pediatric Society, and has served as Trea-surer of the drug metabolism section of the international Union of Pharmacology (iUPhAR; 2006-2012), and currently is a member of the Pharmacogenetics section of IUPHAR. Other past service to professional societies and task forces include Chair-elect, Chair and Past-Chair of the drug metabolism division of the American society for Pharmacology and experi-mental Therapeutics (ASPET; 2009-2012), two 6-year terms on the American Board of Clini-cal Pharmacology; Vice-Chair (2002-2004) and Chair (2004-2008) of the Pediatric, Perinatal and maternal Pharmacology (Ped) section of the American society for Clinical Pharmacology and therapeutics (AsCPt), and as a member of the strategic Awards task Force and nomi-nation Committee for AsCPt; member of Council for the international society for the study of Xenobiotics (ISSX) from 2000-2003 and Chair of the Exhibits Committee (2003-2005).

Dr. Leeder’s research focuses on the application of pharmacogenetic and pharmacogenomic strategies to characterize the relative contributions of ontogeny, genetic variation, and dis-ease to observed variability in drug disposition and response in children. Clinical application of this research is embodied in the GOLDILOKs initiative at CMH: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids.

Sara Van Driest, MD, PhD, FAAP Dr. Van Driest completed her MD and PhD at the Mayo Clinic College of Medicine in her home state of Minnesota prior to moving to Nashville. There she completed pediatric resi-dency at the Monroe Carell Jr. Children’s Hospital at Vanderbilt, after which she was selected to serve as pediatric chief resident. She remained at Vanderbilt to complete a two year fel-lowship in Clinical Pharmacology under the mentorship of Dan Roden, and then joined the pediatric faculty in the Division of General Pediatrics. She is currently an Assistant Professor of Pediatrics and Medicine at Vanderbilt and a member of the Society for Pediatric Research. As a physician-scientist, sara uses the electronic medical record as a source of “big data” for research and as a tool for implementation of pediatric personalized medicine. She has focused on commonly used medications, including antibiotics, analgesics and sedatives, and the common adverse drug event, acute kidney injury. Sara’s research program has been funded through an NIH KL2, an early career award from the PhRMA Foundation, and an In-novation in Regulatory Science Award from the Burroughs Wellcome Fund.

G. Bradley Schaefer, MD, FAAP Dr. Schaefer is a Professor of Genetics and Pediatrics at the University of Arkansas for Medi-cal Sciences. He is the Founding Director of the Division of Medical Genetics and the Chief of the Section of Genetics and Metabolism in the Department of Pediatrics at UAMS. He is also the Medical Director of the Genetic Counseling Training program at UAMS. He is the inaugu-ral holder of the Committee for the Future Endowed Chair in Medical Genetics.He has achieved board certification in Pediatrics, Human Genetics, and Pediatric Endocrinol-ogy. He is a founding fellow of the American College of Medical Genetics, and a fellow of the American Academy of Pediatrics. He is a member of the American Pediatric Society. He has authored over 250 scientific articles, book chapters, and invited reviews. He is on the editorial board of the Journal of Child Neurology, and sits on the National Advisory Board for the Sotos Syndrome Support Association.

Dr. Schaefer’s clinical and research interests focus on the genetics of neurodevelopmental, neurosensory and neurobehavioral disorders; craniofacial genetics, medical transition for Children with special health Care needs; tele-genetics services; and newborn screening follow up and infrastructure.

about our Featured sPeakers